- Home
- IPHA vs MRCC Comparison
IPHA vs MRCC Comparison
Compare IPHA & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- MRCC
- Stock Information
- Founded
- IPHA 1999
- MRCC 2011
- Country
- IPHA France
- MRCC United States
- Employees
- IPHA N/A
- MRCC N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- IPHA Health Care
- MRCC Finance
- Exchange
- IPHA Nasdaq
- MRCC Nasdaq
- Market Cap
- IPHA 160.1M
- MRCC 176.4M
- IPO Year
- IPHA 2019
- MRCC 2012
- Fundamental
- Price
- IPHA N/A
- MRCC $6.46
- Analyst Decision
- IPHA Strong Buy
- MRCC Hold
- Analyst Count
- IPHA 1
- MRCC 1
- Target Price
- IPHA $11.00
- MRCC $8.00
- AVG Volume (30 Days)
- IPHA 11.7K
- MRCC 91.8K
- Earning Date
- IPHA 03-27-2025
- MRCC 08-06-2025
- Dividend Yield
- IPHA N/A
- MRCC 15.67%
- EPS Growth
- IPHA N/A
- MRCC 3301.50
- EPS
- IPHA N/A
- MRCC 0.32
- Revenue
- IPHA $20,831,349.00
- MRCC $56,983,000.00
- Revenue This Year
- IPHA $209.83
- MRCC N/A
- Revenue Next Year
- IPHA $83.15
- MRCC N/A
- P/E Ratio
- IPHA N/A
- MRCC $19.88
- Revenue Growth
- IPHA N/A
- MRCC N/A
- 52 Week Low
- IPHA $1.29
- MRCC $6.11
- 52 Week High
- IPHA $3.51
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- IPHA 39.24
- MRCC 50.70
- Support Level
- IPHA $1.71
- MRCC $6.19
- Resistance Level
- IPHA $1.90
- MRCC $6.65
- Average True Range (ATR)
- IPHA 0.09
- MRCC 0.15
- MACD
- IPHA -0.00
- MRCC 0.02
- Stochastic Oscillator
- IPHA 40.74
- MRCC 50.88
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.